After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Yahoo Finance discussed the stock recently as it posted Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
This NYSE-listed company operates within the Drug Manufacturers – General industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $161.21 and fluctuated between $161.37 as its day high and $159.69 as its day low. The current market capitalization of Johnson & Johnson is $388.08B. A total of 5.37 million shares were traded on the day, compared to an average of 6.84M shares.
Insider Activity
Insider trades can also provide insight into a stock’s future direction. During the recent three months, JNJ has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 25 BUYs and 34 SELLs from insiders. Insiders purchased 193,748 shares during that period but sold 138,919.
In the most recent transaction, Hait William sold 14,698 shares of JNJ for 172.00 per share on Jul 26. After the transaction, the insider now owns 87,747 company shares. In a previous transaction on Jul 25, Fasolo Peter sold 20,000 shares at 170.32 per share. JNJ shares that Exec VP, Chief HR Officer owns now total 102,696.
Among the insiders who sold shares, Wengel Kathryn E disposed of 12,465 shares on Jun 12 at a per-share price of $160.00. This resulted in the EVP, Chief TO and Risk Officer holding 65,934 shares of JNJ after the transaction. In another insider transaction, Swanson James D. sold 1,062 shares at $154.66 per share on Mar 06. Company shares held by the insider now total 9,215.
Dividend
The income generated by dividends is an indication that a company is improving its financial position, which is why investors prefer companies paying dividends. Johnson & Johnson pays an annual dividend of $4.60, resulting in a dividend yield of 2.86%, and it has a price to earnings (P/E) ratio of 30.77. JNJ’s most recent ex-dividend date was 2/16/2024 when it declared a $1.19 quarterly dividend that was paid in cash on 3/5/2024. Previously, the company paid the dividend on 12/5/2023 with an ex-dividend date of 11/20/2023. The JNJ stock dividend was $1.19 per share in cash.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for JNJ in the last 3 months, the mean price target is $175.42 with high estimates of $215.00 and low estimates of $157.00. In terms of 52-week highs and lows, JNJ has a high of $175.97 and a low of $144.95.
As of this writing, JNJ has an earnings estimate of $2.28 per share for the current quarter. EPS was calculated based on a consensus of 14 estimates, with a high estimate of $2.3 per share and a lower estimate of $2.25. The company reported an EPS of $2.56 in the last quarter, which was -2.30% lower than expectations of $2.62.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. JNJ’s latest balance sheet shows that the firm has $31.61B in Cash & Short Term Investments as of fiscal 2021. There were $33.75B in debt and $45.23B in liabilities at the time. Its Book Value Per Share was $29.59, while its Total Shareholder’s Equity was $74.02B.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for JNJ is Buy with a score of 3.95.
